



Scientific Program

Friday, May 17th 2024

10:00 -10:15 **Congress Opening**

10:15 - 12:30 **Plenary Session 1: Emerging trends in cancer-associated thrombosis (Part I)**

Chairs: *Benjamin Brenner (Israel), Paolo Simioni (Italy)*

Endothelial cell dysfunction in cancer: a modulator of CAT and metastasis?

Jamie O'Sullivan (Ireland)

Artificial Intelligence in CAT

Rushad Patell (USA)

The gut microbiome in cancer and thrombosis

Christoph Reinhardt (Germany)

Stroke in patients with cancer

Deborah Siegal (Canada)

Selected Abstract

OC01_ IMMUNE CHECKPOINT BLOCKADE PROMOTES THROMBOSIS VIA T-CELL AND NEUTROPHIL ACTIVATION, AND TUMOR-CELL ASSOCIATED TISSUE FACTOR (TF) IN A MURINE MODEL OF COLORECTAL CANCER
Y Shim, B Sharma, Y Hisada, N Mackman, J Palumbo, M Diaz-Montero, A Khorana, Keith McCrae (USA)

OC02_ NAVIGATING THE INTERPLAY OF CANCER, HEMOSTASIS, AND THROMBOSIS: INVESTIGATING TISSUE FACTOR IN COLORECTAL CANCER (CALGB/SWOG 80405)
Sandra Algaze, Y. Yang, J. Millstein, F. Battaglin, S. Soni, P. Mittal, K. Ashouri, A. Wong, P. Jayachandran, H. Arai, J. H. Lo, W. Zhang, L. Torres-gonzalez, H. Liebman, H. J. Lenz (USA)

12:30 -13:30 **Debate: Do we need more complex and specific RAMs for CAT?**

Chairs: *Paolo Prandoni (Italy), Mario Mandalà (Italy)*

YES: *Andres Munoz-Martin (Spain)*

NO: *Ingrid Pabinger (Austria)*

13:30 – 14:30 Lunch Sessions

14:30 – 15:00 Coffee



15:00 – 17:15 **Plenary Session 2: Emerging trends in cancer-associated thrombosis (Part II)**

Chairs: *Laurent Bertoletti (France), Francesco Dentali (Italy)*

Trends and Updates on the Epidemiology of Cancer-Associated Thrombosis

Ang Li (USA)

Cancer immunotherapy in CAT

Claudine Graf (Germany)

Bleeding and thrombosis during CAR-T therapy

Elena Rossi (Italy)

Location of metastasis and complications of anticoagulant treatment

Maria Barca-Hernando (Spain)

Selected Abstracts

OC03_ PREDICTION OF CLINICALLY SIGNIFICANT BLEEDING IN PATIENTS ANTICOAGULATED FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: VALIDATION OF THE B-CAT SCORE IN A COHORT OF PATIENTS FROM THE TESEO STUDY

Javier López Robles, M. Sánchez Cánovas, C. Iglesias, L. Ortega Morán, L. Sánchez Togneri, J. Rubio, I. Fernández Pérez, M. García De Herreros, I. García Escobar, R. Porta, E. Brozos, M. Carmona Campos, E. Martínez De Castro, H. Olivares, T. Quintanar, S. García Adrián, M. Covela Rúa, A. Carmona Bayonas, P. Jiménez Fonseca, Aj. Muñoz Martín, On Behalf of Teseo Registry Investigators (Spain)

OC04_ TISSUE FACTOR PATHWAY-RELATED BIOMARKERS IN PANCREATIC CANCER: PLASMA LEVELS OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX MAY PREDICT VENOUS THROMBOEMBOLISM

Elena Campello, M. Spizzo, A. Castagna, F. T. M. Bosch, F. I. Mulder, N. Van Es, S. Gavasso, P. Pattini, A. Rousseau, P. Van Dreden, S. Friso, H. R. Büller, P. Simioni, N. Martinelli (Italy, The Netherlands, France)

17:15 - 17:45 Coffee Break

17:45 – 18:45 **Plenary Lecture: 8th Simon Karpatkin Memorial Lecture**

The Conference Chairs

Introduction to Lecture: *Alok A. Khorana (USA)*

VTE treatment in patients with cancer: Reflections on an evolving landscape

Agnes Y.Y. Lee (Canada)



Saturday, May 18th 2024

8:30 – 10:45 Plenary Session 3: Anticoagulation in hematological cancer patients

Chairs: *Roberto Santi (Italy), Giancarlo Castaman (Italy)*

VTE and mortality in patients with hematological malignancies

Kristen Sanfilippo (USA)

Management of CAT in thrombocytopenia: the uncertain balance between risks and benefits of platelet transfusion to support anticoagulation

Simon J. Stanworth (UK)

Pharmacological approach to increase platelet count: from ITP to chemotherapy-induced thrombocytopenia

Monica Carpenedo (Italy)

Selected Abstracts

OC05_ THE RISK OF THROMBOEMBOLIC RECURRENCE OUTWEIGHS THE RISK OF MAJOR BLEEDING IN CANCER PATIENTS TREATED WITH TINZAPARIN, EVEN IN PATIENTS WITH FRAGILITY CRITERIA. META-ANALYSIS OF PROSPECTIVE STUDIES INVOLVING 1413 INDIVIDUAL PATIENTS' DATA

Isabelle Mahé, C Chapelle, G. Poenou, L. Jara-palomares, A. Y. Y. Lee, O. Sanchez, G. Meyer, P. Girard, S. Laporte (France, Spain, Canada)

OC06_ RAPID EXCLUSION OF CLINICALLY RELEVANT PLASMA LEVELS OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS USING THE DOAC DIPSTICK IN VARIOUS INDICATIONS

Job Harenberg, W. Ageno, C. Becattini, J. Douxfils, A. Falanga, S. Hetjens, M. Marchetti, J. Vassart, F. Violi, C. Weiss, J Weitz, On Behalf of The Doac Poct Working Group (Germany, Italy, Canada)

10:45 – 11:15 Coffee break



11:15 – 13:30 **Plenary Session 4: Exploring the relationship between hemostasis and cancer:**

New insights

Chairs: *Erica De Candia (Italy), Hugo ten Cate (The Netherlands)*

Platelets: A weapon against cancer

Paolo Gresele (Italy)

FXa inhibitors in cancer progression

Andrea Alimonti (Switzerland)

Coaguloma and tumor microenvironment

Janusz Rak (Canada)

Crosstalk between NETs and tumor progression

Laurence Panicot-Dubois (France)

Selected Abstracts

OC07_ INVESTIGATING A PROPOSED ANTI-CANCER IMMUNITY EFFECT OF RIVAROXABAN IN BREAST CANCER.

U. Singh, John Castle, S. Pritchard, R. Hunt, J. R. Harvey, C. Holcombe, A. Volleamere, B. Hogan, R. Vinayagam, P. G. Roy, M. Bramley, J. Kokan, C. Palmieri, K. Cox, J. Thachil, R. Jackson, A. Marshall, L. Turner, N. J. Bundred, C. C. Kirwan (UK)

OC08_ TUMOR PLATELET TRANSCRIPTOME CHANGES AFFECTED BY MICRO METASTASIS

Carina Dinis Santos Rodrigues, J. Braun, S. Schubert, F. Marini, C. Graf, B. Schrörs, W. Ruf (Germany, USA)

13:30 – 14:30 Lunch

14:30 – 15:00 Coffee

15:00 – 17:00 Poster Discussion Sessions

Poster Session 1: Biomarkers/Hypercoagulability I

Chair: Norma Maugeri (Italy)

Poster Session 2: Thrombohemorrhagic complications

Chair: TBA

Poster Session 3: Epidemiology

Chair: Marina Marchetti (Italy)

Poster Session 4: Thromboprophylaxis in cancer

Chair: TBA



Poster Session 5: Treatment of thrombosis in cancer

Chair: Elvira Grandone (Italy)

Poster Session 6: Hemostatic proteins and cancer biology

Chair: TBA

Poster Session 7: Therapeutic challenges

Chair: Mariasanta Napolitano (Italy)

Poster Session 8: Biomarkers/Hypercoagulability II

Chair: Francesca Schieppati (Italy)

17:00 – 18:15 Interactive session: Spotlight on prevention of VTE in cancer patients

Chair: *Ajay K. Kakkar (UK)*

A case of thrombosis in medical patient

Walter Ageno (Italy)

A case of thrombosis in surgical patient

Giancarlo Agnelli (Italy)

A case of thrombosis during anti-cancer drug treatment

Marina Elena Cazzaniga (Italy)

Discussant: *Anna Falanga (Italy)*

18:15 – 19:00 Special "Noble" Session

Chairs: *Anna Falanga (Italy), Caterina Rizzi (Italy)*

Patient and Public Involvement in CAT Research: Necessary or glorified tokenism?

Simon Noble (UK)



Sunday, May 19th 2024

8:30 – 10:15 Plenary Session 5: Past, present, and future of CAT - A Round Table Discussion

Chairs: *Elvira Grandone (Italy), Alok A. Khorana (USA)*

New drugs, old problems: Immune checkpoint inhibitors and CAT

Alok A. Khorana (USA)

Real-world Outcomes Data for DOAC vs LMWH vs other Anticoagulants: Promises and Pitfalls

Nicole Kuderer (USA)

FXI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

Marcello Di Nisio (Italy)

General Discussion

10:15 – 11.45 Plenary session 6: Novel biomarkers for predicting clinical outcomes in cancer patients

Chairs: *Marina Marchetti (Italy), Andrea Remuzzi (Italy)*

Proteomics prediction of CAT and mechanistic insights

Jeffrey Zwicker (USA)

Age-related clonal hemopoiesis and thrombosis

Liran I. Shlush (Israel)

Machine Learning for the prediction of CAT

Simon Mantha (USA)

Selected Abstracts

OC09_ GROWTH DIFFERENTIATION FACTOR-15 IS ASSOCIATED WITH RISK OF MAJOR BLEEDING IN CANCER PATIENTS WITHOUT ANTICOAGULATION: RESULTS FROM A PROSPECTIVE COHORT STUDY

Cornelia Englisch, S. Nopp, I. Pabinger, F. Moik, D. Steiner, A. M. Starzer, M. Fritzer-szekeres, M. Preusser, A. S. Berghoff, C. Ay (Austria)

OC010_ PREDICTIVE VALUE OF ACTIVATED FXI-ANTITHROMBIN COMPLEX IN CANCER ASSOCIATED THROMBOSIS (CAT): A PROSPECTIVE COHORT STUDY IN LUNG CANCER PATIENTS

Patricia Gomez-Rosas, M. Marchetti, M. Nagy, H. M. H. Spronk, L. Russo, C. Verzeroli, S. Gamba, C. J. Tartari, S. Bolognini, C. Ticozzi, F. Schieppati, R. Sarmiento, F. De Braud, G. Masci, C. Tondini, F. Petrelli, F. Giuliani, A. D'alessio, A. Santoro, G. Gasparini, R. Labianca, H. T. Cate, A. Falanga, On Behalf Of The Hypercan Investigators (Italy)

11:45 - 12:45 *Lunch*



12:45 – 14:35 Plenary Session 7: Anticoagulation in cancer patients

Chairs: *Anna Falanga (Italy), Roberto Labianca (Italy)*

Risk of recurrent VTE in cancer patients after discontinuation of anticoagulant therapy

Gary E Raskob (USA)

Extended antithrombotic prophylaxis after cancer surgery

Cecilia Becattini (Italy)

Trends in the management of pediatric and adolescent patients with cancer-associated VTE

Gili Kenet (Israel)

Selected Abstracts

OC11_MANAGING A CANCER-ASSOCIATED THROMBOSIS CLINIC - OPPORTUNITIES AND CHALLENGES.

Shahid Gilani, D. Chandra (United Kingdom)

OC12_PROGNOSTIC FACTORS ASSOCIATED WITH RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS

F Khan, T Tritschler, Ce Marx, V Lanting, B Rochweg, A Tran, S Fernando, D Lorenzetti, H Wunsch, J Holodinsky, K Fiest, Ht Stelfox, A Delluc, D Fergusson, G Le Gal, P Wells, N Van Es, J M Connors, Marc Carrier (Canada, USA, Switzerland, The Netherlands)

14:35 – 14:40 Concluding Remarks